Pharmaceutical

TRACON Pharmaceuticals (NASDAQ:TCON), announced that positive initial clinical data from its ongoing Phase 1b/2 study of TRC105 and Nexavar® (sorafenib) in patients with advanced hepatocellular carcinoma were presented in a poster presentation at the 2018 ASCO Gastrointestinal Cancers Symposium in San Francisco, California. As quoted in the press release: Charles Theuer, M.D., Ph.D., President and …

TRACON Pharmaceuticals (NASDAQ:TCON), announced that positive initial clinical data from its ongoing Phase 1b/2 study of TRC105 and Nexavar® (sorafenib) in patients with advanced hepatocellular carcinoma were presented in a poster presentation at the 2018 ASCO Gastrointestinal Cancers Symposium in San Francisco, California.
As quoted in the press release:

Charles Theuer, M.D., Ph.D., President and CEO of TRACON said, “Importantly, the initial data from the current trial are consistent with the 33% partial response rate by RECIST 1.1 reported in the completed Phase 1/2 study published by the National Cancer Institute in 2017. We expect to complete enrollment of the current multicenter study by the end of 2018, and will discuss a potential registration-enabling study of the combination of TRC105 and Nexavar in HCC with regulatory authorities shortly thereafter.”

Click here to read the full press release.

MARKETS

Markets
TSX19222.74-35.58
TSXV644.91-7.45
DOW30946.99-491.27
S&P 5003821.55-78.56
NASD11181.54-343.01
ASX6763.60+57.60

COMMODITIES

Commodities
Gold1821.13+2.56
Silver20.81-0.01
Copper3.72-0.06
Palladium1918.95+49.95
Platinum919.00+9.00
Oil110.96-0.80
Heating Oil4.08-0.04
Natural Gas6.72+0.15

DOWNLOAD FREE REPORTS

×